BRVE.US Braveheart Bio, Inc. Common Stock
- Market cap
- USD 1.77B
- P/E
- -
- P/B
- 3.71x
- ROE
- -14.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BRVE.US undervalued?
Graham numberThe Graham number of Braveheart Bio, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Braveheart Bio, Inc. Common Stock fundamental analysis
No fundamental analysis for Braveheart Bio, Inc. Common Stock yet.
Braveheart Bio, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Full company profileBraveheart Bio, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Braveheart Bio, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2025 | 2026 Anlz |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -66.7M | -81.2M |
| EBITDA | -66.7M | -81.2M |
| Net Income | -66.7M | -74.4M |
| EPS | -5.38 | -1.43 |
| Balance Sheet | ||
| Total Assets | 89.4M | 514M |
| Total Liabilities | 5.33M | 16.8M |
| Shareholders' Equity | 84.0M | 498M |
| Cash & Short-term Investments | 89.2M | 349M |
| Total Debt | - | 515K |
| Cash Flow | ||
| Operating Cash Flow | -2.01K | -62.0M |
| Capital Expenditure | 33.6M | 58.7K |
| Free Cash Flow | -2.01K | -62.0M |
| Ratios | ||
| ROE | -79.4% | -14.9% |
| ROA | -74.7% | -14.5% |
| Debt to Equity | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Braveheart Bio, Inc. Common Stock dividends
Braveheart Bio, Inc. Common Stock has not paid dividends in the last 1 fiscal years.
Who owns Braveheart Bio, Inc. Common Stock
- Insiders 58.52%
- Institutions 35.55%
- Public & others 5.93%
- Shares outstanding 90.0M
- Free float 14.0M
Top funds holding BRVE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 2.27M | 3.22% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 780K | 1.10% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 718K | 1.02% | +19.70% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 717K | 1.02% | +1,566.07% | Sep 2026 |
| Fidelity Select Health Care | 537K | 0.76% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 500K | 0.71% | +88.23% | Sep 2026 |
| Fidelity Small Cap Growth | 465K | 0.66% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 350K | 0.49% | +100.42% | Sep 2026 |
| MFS New Discovery I | 346K | 0.49% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 260K | 0.37% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 243K | 0.34% | 0.00% | Aug 2026 |
| Fidelity Series Stk Selec Lg Cp Val | 238K | 0.34% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 224K | 0.32% | 0.00% | Aug 2026 |
| Fidelity VIP Health Care Initial | 190K | 0.27% | +92.81% | Sep 2026 |
| Fidelity Series Growth Company | 188K | 0.27% | 0.00% | Aug 2026 |
| T. Rowe Price Small-Cap Value | 178K | 0.25% | 0.00% | Sep 2026 |
| Fidelity Stock Selec | 176K | 0.25% | +0.18% | Sep 2026 |
| MFS VIT New Discovery Init | 118K | 0.17% | -7.66% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 117K | 0.17% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 116K | 0.16% | +0.22% | Oct 2026 |
Braveheart Bio, Inc. Common Stock company profile
- Company name
- Braveheart Bio, Inc. Common Stock
- Ticker
- BRVE.US
- Exchange
- USA Stocks
- Listed since
- Aug 6, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- One Letterman Drive, San Francisco, CA, United States, 94129
- Phone
- 415 707 6312
- Website
- braveheart.bio
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Braveheart Bio, Inc. Common Stock management
10- Dr. Travis Murdoch B.S., M.D., M.Sc.CEO, President & Director · born 1985
- Mr. James Paul Rickey CPAChief Financial Officer · born 1979
- Ms. Michele A. AndersonChief Development Officer · born 1967
- Mr. Marc Evanchik M.S.Chief Scientific Officer · born 1973
- Ms. Natalie Dement J.D.VP & Head of Legal
- Mr. Timothy Y. ZhouDirector of Corporate Development
- Ms. Steph PalenciaAssociate Director of Human Resources & Office Manager
- Ms. Brittany de TempleSenior Vice President of Development Operations
- Dr. Emil M. deGoma M.D.Chief Medical Officer · born 1976
- Mr. Tyler Chavez Ph.D.Chief Business Officer · born 1989